FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. Common Stock (FBLG) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
fblg · stock forecast · 4 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Buy
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$180
Consensus
$180
+17721.8% upside
Low
$180
Median: $180 · Last Close: $1.01
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.00 | ↓ 1.45% |
1-day model range: $0.97–$1.02. Peak: $1.02 (-1.45%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · FBLG · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-04 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2026-04-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-26 | D. Boral Capital | Downgrade ↓ | Buy→Hold |
| 2026-03-12 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-02-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-25 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-01-06 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-01-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-20 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on FibroBiologics, Inc. Common Stock (FBLG) stock. Of the recent 32 rating actions, 0 were upgrades and 2 were downgrades. 4 analysts currently cover FBLG.
Analyst Recommendation Trends
FBLG analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-3.42
EPS Next Year
$-2.98
↓ 12.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast FBLG EPS of $-3.42 for the current fiscal year, based on estimates from 1 analysts. The FBLG revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The FBLG stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FBLG price target is $180.00 (+17721.8% upside), with an analyst consensus of Buy.
The FBLG short-term stock prediction for tomorrow is $1.00 (-1.45%).
FibroBiologics, Inc. Common Stock trades on NASDAQ under the ticker FBLG. The FBLG stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
FBLG forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month FBLG price target is $180.00, with a high forecast of $180.00 and a low of $180.00. The median price target is shown in the chart above when available. This implies +17721.8% potential upside from the current price of $1.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.